Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +7.31% | +6.82% | +88.00% |
16/04 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
16/04 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Business Summary
Number of employees: 5
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Intellectual Property Licensing
64.9
%
| 0 | 21.4 % | 0 | 64.9 % | +169.06% |
Business-to-business Product
19.5
%
| 0 | 44.4 % | 0 | 19.5 % | -61.07% |
Research & Development
15.6
%
| 0 | 21.5 % | 0 | 15.6 % | -35.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -11.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
John Docherty
PSD | President | 53 | 15/15/15 |
George Jurcic
IRC | Investor Relations Contact | - | 01/21/01 |
Vanessa Carle
LAW | General Counsel | - | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 08/11/08 |
Albert Reese
BRD | Director/Board Member | 74 | 14/21/14 |
John Docherty
PSD | President | 53 | 15/15/15 |
Director/Board Member | 76 | 16/15/16 | |
Catherine Turkel
BRD | Director/Board Member | 63 | 02/22/02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,885,673 | 11,780,368 ( 91.42 %) | 0 | 91.42 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.00% | 30.28M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LEXX Stock
- Company Lexaria Bioscience Corp.